Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPY003-207 in Healthy Participants
NCT06873724Phase 1Active, not recruiting
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- Mar 2025
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of SPY003 (6 arms), sponsored by Spyre Therapeutics, Inc. Primary endpoint: Treatment Emergent Adverse Events up to 63 weeks. Started Mar 2025; status: active, not recruiting.
02
Drugs
SPY003
Beyond the preview
Go deeper on NCT06873724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873724.